Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. - Schlaich MP; Bellet M; Weber MA; Danaietash P; Bakris GL; Flack JM; Dreier RF; Sassi-Sayadi M; Haskell LP; Narkiewicz K; Wang JG (Lancet (London, England), 2022)